Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 29;14(13):3184.
doi: 10.3390/cancers14133184.

Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019

Saul A Beltran-Ontiveros  1 , Martha A Fernandez-Galindo  2   3 , Jose M Moreno-Ortiz  3 , Jose A Contreras-Gutierrez  4 , Jesus Madueña-Molina  5 , Eliakym Arambula-Meraz  6 , Emir Leal-Leon  6 , Delia M Becerril-Camacho  7 , Veronica J Picos-Cardenas  5 , Carla Angulo-Rojo  5 , Diana Z Velazquez  8 , Francisco Jimenez-Trejo  9 , Francisco Gallardo-Vera  10 , Daniel Diaz  11
Affiliations

Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019

Saul A Beltran-Ontiveros et al. Cancers (Basel). .

Abstract

In 2019, the Global Burden of Disease (GBD) estimated that prostate cancer (PC) was the 16th most common cause of death globally in males. In Mexico, PC epidemiology has been studied by a number of metrics and over various periods, although without including the most up-to-date estimates. Herein, we describe and compare the burdens and trends of PC in Mexico and its 32 states from 2000 to 2019. For this study, we extracted online available data from the GBD 2019 to estimate the crude and age-standardized rates (ASR per 100,000 people) of the incidence and mortality of PC. In Mexico, PC caused 27.1 thousand (95% uncertainty intervals, 20.6-36.0 thousand) incident cases and 9.2 thousand (7.7-12.7 thousand) deaths in males of all ages in 2019. Among the states, Sinaloa had the greatest ASR of incidence, and Guerrero had the highest mortality. The burden of PC showed an increasing trend, although the magnitude of change differed between metrics and locations. We found both an increasing national trend and subnational variation in the burden of PC. Our results confirm the need for updated and timely estimates to design effective diagnostic and treatment campaigns in locations where the burden of PC is the highest.

Keywords: age-standardized rate; burden of disease; cancer epidemiology; malign neoplasm; sociodemographic index; subnational heterogeneity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interest for this study.

Figures

Figure 1
Figure 1
Change in the subnational age-standardized (a) incidence and (b) deaths per 100,000 people due to prostate cancer in Mexico from 2000 to 2019.
Figure 2
Figure 2
(a) Prostate cancer burden by age group and rate per 100,000 people in Mexico in 2019; (b) relative contribution per age group to the counts of incident cases and deaths; and (c) contribution per age group to the annual number of deaths due to prostate cancer in Mexico from 2000 to 2019.
Figure 3
Figure 3
National trends of (a) prostate cancer incidence and death counts; (b) age-standardized rates per 100,000 people in Mexico from 2000 to 2019; and (c) percentage of change in the burden of prostate cancer from 2010 to 2019 at the subnational level. In (b), the insert shows the subnational trends, including the names of the states with the highest and lowest rates for 2019.
See this image and copyright information in PMC

References

    1. Ferlay J., Ervik M., Lam F., Colombet M., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. [(accessed on 12 January 2022)]. Available online: https://gco.iarc.fr/today/home.
    1. Vos T., Lim S.S., Abbafati C., Abbas K.M., Abbasi M., Abbasifard M., Abbasi-Kangevari M., Abbastabar H., Abd-Allah F., Abdelalim A., et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9. - DOI - PMC - PubMed
    1. Global Burden of Disease 2019 Cancer Collaboration. Kocarnik J.M., Compton K., Dean F.E., Fu W., Gaw B.L., Harvey J.D., Henrikson H.J., Lu D., Pennini A., et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420–444. doi: 10.1001/jamaoncol.2021.6987. - DOI - PMC - PubMed
    1. Lajous M., Cooperberg M.R., Rider J., Manzanilla-Garcia H.A., Gabilondo-Navarro F.B., Rodriguez-Covarrubias F.T., Lopez-Ridaura R., Torres-Sanchez L.E., Mohar A. Prostate cancer screening in low- and middle-income countries: The Mexican case. Salud Pública De México. 2019;61:542–544. doi: 10.21149/10373. - DOI - PMC - PubMed
    1. Sierra M.S., Soerjomataram I., Forman D. Prostate cancer burden in Central and South America. Cancer Epidemiol. Prev. Biomark. 2016;44((Suppl. S1)):S131–S140. doi: 10.1016/j.canep.2016.06.010. - DOI - PubMed

LinkOut - more resources